The latest evidence for possible HIV-1 curative strategies

Human immunodeficiency virus type 1 (HIV-1) infection remains a major health issue worldwide. In developed countries, antiretroviral therapy has extended its reach from treatment of people living with HIV-1 to post-exposure prophylaxis, treatment as prevention, and, more recently, pre-exposure prophylaxis. These healthcare strategies offer the epidemiological tools to curve the epidemic in rich settings and will be concomitantly implemented in developing countries. One of the remaining challenges is to identify an efficacious curative strategy. This review manuscript will focus on some of the current curative strategies aiming at providing a sterilizing or functional cure to HIV-1-positive individuals. These include the following: early treatment initiation in post-treatment controllers as a long-term HIV-1 remission strategy, latency reversal, gene editing with or without stem cell transplantation, and antibodies against either the viral envelope protein or the host integrin α4β7.

• Publication year

  2018

• Venue

  Drugs in Context

• Publication date

  2018-02-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.7573/dic.212522PMID 29497452PMCID 5824924
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection

  2018cited by this paper
• HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity

  2017cited by this paper
• Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression

  2017cited by this paper
• Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells

  2017cited by this paper
• Targeted Immune Interventions for an HIV-1 Cure.

  2017cited by this paper
• HIV drug resistance against strand transfer integrase inhibitors

  2017cited by this paper
• Sustained virologic control in SIV+ macaques after antiretroviral and alpha(4)beta(7) antibody therapy

  2017cited by this paper
• Immune checkpoint blockade in infectious diseases

  2017cited by this paper
• Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

  2017cited by this paper
• OA3-3 Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T cells

  2017cited by this paper
• CRISPR/Cas9: a double-edged sword when used to combat HIV infection

  2016cited by this paper
• Broadly Neutralizing Antibodies for HIV Eradication

  2016cited by this paper
• Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS

  2016cited by this paper
• The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence

  2016cited by this paper
• A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells

  2016cited by this paper
• CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape.

  2016cited by this paper
• Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy

  2016cited by this paper
• Might dolutegravir be part of a functional cure for HIV?

  2016cited by this paper
• TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

  2016cited by this paper
• Immune checkpoints and the HIV-1 reservoir: proceed with caution

  2016cited by this paper
• HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.

  2016cited by this paper
• Broad activation of latent HIV-1 in vivo

  2016cited by this paper
• The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA

  2015cited by this paper
• Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

  2015cited by this paper
• Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy

  2015cited by this paper
• Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

  2015cited by this paper
• Viremic relapse after HIV-1 remission in a perinatally infected child.

  2015cited by this paper
• HIV–1 resistance to dolutegravir: update and new insights

  2015cited by this paper
• Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism

  2015cited by this paper
• Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation

  2015cited by this paper
• A High Excision Potential of TALENs for Integrated DNA of HIV-Based Lentiviral Vector

  2015cited by this paper
• Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1

  2015cited by this paper
• Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma.

  2015cited by this paper
• HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.

  2015cited by this paper
• mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5

  2015cited by this paper
• Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization

  2015cited by this paper
• Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

  2015cited by this paper
• Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation

  2014cited by this paper
• Bryostatin Activates HIV-1 Latent Expression in Human Astrocytes through a PKC and NF-kB-Dependent Mechanism

  2014cited by this paper
• More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation.

  2014cited by this paper
• Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

  2014cited by this paper
• RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection

  2014cited by this paper
• More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation.

  2014cited by this paper
• Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection.

  2014cited by this paper
• Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

  2014influential reference
• Targeting α4β7 integrin reduces mucosal transmission of SIV and protects GALT from infection

  2014cited by this paper
• Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.

  2014cited by this paper
• Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

  2014cited by this paper
• Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation

  2013cited by this paper
• Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells

  2013cited by this paper
• Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus

  2013cited by this paper
• Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers

  2013cited by this paper
• Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient

  2013cited by this paper
• Absence of detectable HIV-1 viremia after treatment cessation in an infant.

  2013cited by this paper
• Interleukin-7 promotes HIV persistence during antiretroviral therapy.

  2013cited by this paper
• Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys

  2013cited by this paper
• The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.

  2013cited by this paper
• Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

  2013cited by this paper
• Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease

  2013cited by this paper
• A Randomized Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection

  2012cited by this paper
• Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

  2012cited by this paper
• Reactivation of latent HIV-1 by a wide variety of butyric acid-producing bacteria

  2012cited by this paper
• Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.

  2012cited by this paper
• The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation

  2012cited by this paper
• Role of PD-1 in HIV Pathogenesis and as Target for Therapy

  2012cited by this paper
• Overcoming Transcription Activator-like Effector (TALE) DNA Binding Domain Sensitivity to Cytosine Methylation*♦

  2012cited by this paper
• Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients

  2012cited by this paper
• Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses

  2012cited by this paper
• Developing strategies for HIV-1 eradication.

  2012cited by this paper
• Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

  2012cited by this paper
• Blocking of α4β7 Gut-Homing Integrin during Acute Infection Leads to Decreased Plasma and Gastrointestinal Tissue Viral Loads in Simian Immunodeficiency Virus-Infected Rhesus Macaques

  2011cited by this paper
• Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1

  2011cited by this paper
• HDAC1/NFκB pathway is involved in curcumin inhibiting of Tat‐mediated long terminal repeat transactivation

  2011cited by this paper
• Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir

  2011cited by this paper
• Plasmacytoid dendritic cells are recruited to the colorectum and contribute to immune activation during pathogenic SIV infection in rhesus macaques.

  2011cited by this paper
• Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

  2011cited by this paper
• CCR5: From Natural Resistance to a New Anti-HIV Strategy

  2010cited by this paper
• The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

  2010cited by this paper
• A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

  2010cited by this paper
• Involvement of Histone H3 Lysine 9 (H3K9) Methyltransferase G9a in the Maintenance of HIV-1 Latency and Its Reactivation by BIX01294*

  2010cited by this paper
• Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

  2010cited by this paper
• Inhibition of HIV‐1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction

  2010cited by this paper
• Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo

  2010cited by this paper
• The biology of CCR5 and CXCR4

  2009cited by this paper
• The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

  2009cited by this paper
• The Use of Darunavir/Ritonavir as Intensification in Low Viremic HIV-Infected Patients Treated with Boosted Protease Inhibitor-Containing Regimens

  2009cited by this paper
• Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

  2009cited by this paper
• Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L

  2009cited by this paper
• "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence

  2009cited by this paper
• Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection

  2009cited by this paper
• Pharmaceutical approaches to eradication of persistent HIV infection

  2009cited by this paper
• Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

  2009cited by this paper
• The integrin α4β7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1

  2009cited by this paper
• Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

  2008cited by this paper
• HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

  2008cited by this paper
• Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir

  2008cited by this paper
• Valproic acid as anti-cancer drug.

  2007cited by this paper
• Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction

  2007cited by this paper
• Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection

  2007cited by this paper
• HIV-1 Proviral DNA Excision Using an Evolved Recombinase

  2007cited by this paper

• The Possibilities of Finding a Cure for HIV

  2025influential citation
• Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication

  2025cites this paper
• Ganoderma lucidum: Insight into antimicrobial and antioxidant properties with development of secondary metabolites

  2024cites this paper
• The immunosuppressive tuberculosis-associated microenvironment inhibits viral replication and promotes HIV-1 latency in CD4+ T cells

  2023cites this paper
• Enhanced Solubility and Dissolution of Drug-drug Cocrystals of Lopinavir-Ritonavir

  2023cites this paper
• Lopinavir-menthol co-crystals for enhanced dissolution rate and intestinal absorption

  2022cites this paper
• Resveratrol Promotes HIV-1 Tat Accumulation via AKT/FOXO1 Signaling Axis and Potentiates Vorinostat to antagonize HIV-1 latency.

  2021cites this paper
• HIV-1 Envelope Glycosylation and the Signal Peptide

  2021cites this paper
• Computational Approaches for Designing Highly Specific and Efficient sgRNAs.

  2021cites this paper
• CRISPR-Cas9 Potential in Eradicating HIV Latent Reservoir as The Up-to-date Therapy For HIV-1

  2021cites this paper
• Predictors of antiretroviral therapy interruptions and factors influencing return to care at the Nkolndongo Health District, Cameroon

  2021cites this paper
• Timing, Dosage, and Adherence of Antiretroviral Therapy and Risk of Osteoporosis in Patients With Human Immunodeficiency Virus Infection in Taiwan: A Nested Case-Control Study

  2021cites this paper
• Chinese Herbal Medicine Usage Reduces Overall Mortality in HIV-Infected Patients With Osteoporosis or Fractures

  2021cites this paper
• HIV INFECTION CURE STRATEGIES: BASIC METHODOLOGICAL APPROACHES AND DIFFICULTIES OF THEIR IMPLEMENTATION

  2020cites this paper
• Variations in Trim5α and Cyclophilin A genes among HIV-1 elite controllers and non controllers in Uganda: a laboratory-based cross-sectional study

  2020cites this paper
• Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly

  2020influential citation
• СТРАТЕГИИ ИЗЛЕЧЕНИЯ ВИЧ-ИНФЕКЦИИ: ОСНОВНЫЕ МЕТОДОЛОГИЧЕСКИЕ ПОДХОДЫ И ПРОБЛЕМЫ ИХ РЕАЛИЗАЦИИ

  2020cites this paper
• Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics

  2020influential citation
• Use of CRISPR to Enhance and Combat Human Viral Infections as HIV and SARS-Cov-2

  2020cites this paper
• Re-examining the HIV ‘functional cure’ oxymoron: Time for precise terminology?

  2020cites this paper
• A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure

  2020cites this paper
• Revisiting the ‘sterilising cure’ terminology: a call for more patient-centred perspectives on HIV cure-related research

  2019cites this paper
• Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow

  2019cites this paper
• Prevalence of CCR5delta32 in Northeastern Iran

  2019cites this paper
• Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screens

  2019cites this paper
• Protein and Glycan Mimicry in HIV Vaccine Design

  2019cites this paper
• Impact of LEDGIN treatment during virus production on residual HIV-1 transcription

  2019cites this paper
• Clinical pharmacology in HIV cure research – what impact have we seen?

  2019cites this paper
• The Role of CS1 Fibronectin in HIV-1 Infection of α4β7+ T Lymphocytes

  2018cites this paper
• Impact des inhibiteurs de l'intégrase sur la constitution et la compartimentalisation du réservoir viral

  2018cites this paper
• Définition d’épitopes CTL dans l’ADN VIH-1 archivé et présentables par le HLA-B : perspective vaccinale

  2018cites this paper
• Annual LDI Scientific Retreat Friday May 4 , 2018 8 : 15 am — 5 : 30 pm

  2018cites this paper
• Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs

  2018cites this paper
• Harnessing CRISPR to combat human viral infections.

  2018cites this paper
• Construction and molecular analysis of hepatitis B virus core 1-144 + human immunodeficiency virus Gag recombination from Indonesian isolates

  2018cites this paper